BANGKOK — Thailand has signed a deal to procure 26 million doses of the trial coronavirus vaccine developed by pharmaceutical firm AstraZeneca in collaboration with Oxford University.
The doses expected to be delivered in mid-2021 would cover 13 million people in a population of about 69 million.
Thailand’s National Vaccine Institute signed a non-refundable advance market commitment contract worth 2.38 billion baht ($79 million) with AstraZeneca to reserve the supply of the vaccine candidate. Another 3.67 billion baht ($121 million) agreement for the purchase of the trial vaccine, known as AZD1222, was signed by the Health Ministry’s Disease Control Department.
A government spokesman said Friday that officials are still deciding who should receive the vaccine first. A separate deal signed in October allows a Thai company to manufacture the AstraZeneca vaccine. Thailand has had 3,961 confirmed cases of the coronavirus since January, including 60 deaths.